Board of Directors
Dr. Tony Wild, CHAIRMAN
Dr. Wild has over 30 years experience working in the pharmaceutical industry. He has held senior positions in Warner Lambert's Parke-Davis division, Schering Plough and MedPointe Pharmaceuticals. Dr. Wild is a co-founder and General Partner of BOWS Pharmaceuticals AG, a Swiss drug-delivery technology company. He is a member of the Boards of Directors of several privately-owned specialty pharmaceutical and biotechnology companies. He also chairs the board of advisors of Ferrer, Freeman and Co., a healthcare private equity firm. He is on the board of advisors of Celtic Therapeutics, a pharmaceutical venture fund and is an advisor to Golden Pond Healthcare Inc., a special acquisitions corporation.
Dr. Wild graduated in 1968 from the University of York where he earned an honors degree in Chemistry. He also holds a Ph.D. degree in physical chemistry from the University of Cambridge (Churchill College).
Rolf Schmidt, DIRECTOR
Mr. Schmidt was co-founder of the medical bio-adhesives product company, Closure Medical Corporation together with his brother William Schmidt. He led the company as Chairman from its early development through IPO in 1996 and up until its acquisition by Johnson & Johnson in 2005. Mr. Schmidt's training and business experience is concentrated mainly in engineering and management roles. He was co-founder of Sharpoint, Inc. a leading developer and manufacturer of ophthalmic surgical needles and sutures prior to its acquisition by Alcon Labs, Inc. in 1986. Mr. Schmidt actively consults with and invests in early-stage healthcare technology companies.
Michael Myers, Ph.D., DIRECTOR
Dr. Michael Myers is President and Chief Executive Officer of Innocoll Inc. He has over 20 years active experience in the pharmaceutical industry in the US and Europe with a proven track record of development and commercialization of a number of significant drug delivery products across a wide variety of delivery routes. He has served as President of the Drug Delivery division of West Pharmaceutical Services and formerly as President of Pharmaceutical Operations for Fuisz Technologies (Biovail) where he oversaw the development and commercialization of the Company's FlashDose® technology platform. Michael has also held executive positions in Flamel Technologies and Elan Corporation. Michael holds a Ph.D. in Organic Chemistry from the University of Cork.
Gordon Dunn, DIRECTOR
Gordon Dunn has managed NewSmith Capital's Private Equity funds since their inception in 2004. Prior to joining NewSmith Gordon had over 12 years' experience in the banking and securities industry and as a securities lawyer, including nine years with Merrill Lynch in London. Prior to joining NewSmith, Gordon was Co-Head of the Merrill Lynch European Private Equity Group from 2000 to 2002. Gordon began his career as an associate at the law firm Morrison & Foerster. He received a Bachelor of Arts, with distinction, from Stanford University and a JD from New York University School of Law.
John O'Meara, DIRECTOR
John O'Meara has over 7 years experience in the finance industry. He is currently a Vice President in Morgan Stanley's credit trading business in the Fixed Income Division of Sales and Trading. As a previous member of Morgan stanley's High Yield Research Team from 2003 - 2007, Mr. O'Meara was a published analyst of High Yield Research. Mr. O'Meara joined the trading desk in 2008 where his responsibilities include reviewing investing opportunities, corporate restructurings and capital market transaction. Mr. O'Meara holds a B.A. in Economics from University of California, Davis.